Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

Hematological Oncology

Volumn 33, Issue 2, 2015, Pages 57-66

  Silverman, Lewis R ^a   Greenberg, Peter ^b   Raza, Azra ^c   Olnes, Matthew J ^d   Holland, James F ^a   Reddy, Premkumar ^a   Maniar, Manoj ^e   Wilhelm, Francois ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Onconova Therapeutics Inc   (United States)

Author keywords

DNA methyl transferase inhibitors; Myelodysplastic syndromes; ON 01910.Na; Phosphatidylinositol 3 kinase; Polo like kinase; Rigosertib

Indexed keywords

AZACITIDINE; DECITABINE; RIGOSERTIB; CELL CYCLE PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR; GLYCINE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SULFONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DYSURIA; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; INFUSION PUMP; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; THROMBOCYTE COUNT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTAGONISTS AND INHIBITORS; BONE MARROW; DNA METHYLATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; META ANALYSIS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RISK; SIGNAL TRANSDUCTION; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BONE MARROW; CELL CYCLE PROTEINS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLYCINE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RISK; SIGNAL TRANSDUCTION; SULFONES;

EID: 84930900277     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2137     Document Type: Article

References (28)

1. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004; 41: 6-12.
2. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
3. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
5. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
6. Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the Gruppo Romano Mielodisplasie Italian regional database. J Clin Oncol 2013; 31: 2671-2677.
7. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100: 1542-1551.
8. Fenaux P, Ades L. Review of azacitidine trials in intermediate-2-and high-risk myelodysplastic syndromes. Leuk Res 2009; 33(Suppl 2): S7-S11.
9. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109: 265-273.
10. Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion 2012; 52: 2131-2138.
11. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116: 3830-3834.
12. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322-3327.
13. Reddy MV, Venkatapuram P, Mallireddigari MR, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2', 4', 6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 2011; 54: 6254-6276.
14. Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 275-286.
15. Prasad A, Park IW, Allen H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009; 28: 1518-1528.
16. Chun AW, Cosenza SC, Taft DR, Maniar M. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 2009; 65: 177-186.
17. Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012; 36: 982-989.
18. Seetharam M, Fan AC, Tran M, et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 2012; 36: 98-103.
19. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
20. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
21. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012; 118: 4471-4477.
22. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072.
23. Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, et al. A phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011; 117: 1253-1261.
24. Soper DM, Huang Y-W, Wilhelm F, et al. Single cell network profiling (SCNP) to evaluate the mechanism of action of ON 01910.Na, a novel clinical trial stage compound. ASH Annual Meeting Abstracts. 2009;114(22):3827.
25. Skidan I, Zinzar S, Holland JF, Reddy R, Reddy EP, Silverman LR. Toxicology of a novel small molecule ON 1910.Na on human bone marrow and leukemic cells in vitro. AACR Annual Meeting. 2006:Abstr. 309.
26. Chen D, Zinzar S, Cosenza S, Reddy E, Holland J, Silverman L. Novel anticancer agent ON 01910.Na induces phosphorylation of cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest and apoptosis of human leukemia cells. AACR Annual Meeting Abstracts. 2008: Abstr. 5081.
27. Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk Res 2012; 36: 1453-1458.
28. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.